Article

Functional vision restored in Leber's congenital amaurosis patients

Gene therapy has resulted in functional vision for patients with Leber's congenital amaurosis (LCA), said Albert Maguire, MD, of the University of Pennsylvania, Bryn Mawr. That research is the result of a 13-year effort by Dr. Maguire and colleagues.

Gene therapy has resulted in functional vision for patients withLeber's congenital amaurosis (LCA), said Albert Maguire, MD, ofthe University of Pennsylvania, Bryn Mawr. That research is theresult of a 13-year effort by Dr. Maguire and colleagues.

Their previous well-known work involved successfully delivering aviral vector into dogs with LCA. The dogs lacked the RPE65 geneneeded to process vitamin A. Successful restoration of vision indogs treated with a subretinal injection of the viral vectorcontaining RPE65 was the basis for the clinical work inhumans.

In a phase I clinical safety trial, three groups of threepatients each were treated in one eye only with a subretinalinjection of either a low-, medium-, or high-dose of the RPE65vector, Dr. Maguire said. The treated eye then was evaluated fora response and compared with the untreated fellow eye.

"All patients in the low-dose cohort had substantial visualacuity improvement," he said. Visual field testing indicated thatthe visual fields were larger in the treated eyes compared withthe control eyes. In addition, the patients' pupils alsoresponded to light despite a flat electroretinogram.

Dr. Maguire emphasized that the vision was indeed functional, andhe demonstrated patients navigating an obstacle course "quicklyand confidently," which previously had been an impossibletask.

Results of the study were published in April 2008 in the NewEngland Journal of Medicine.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.